Dr. Trinh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4025 N Sheridan Rd
Chicago, IL 60613Phone+1 773-388-1600Fax+1 773-388-8936
Summary
- Dr. Roger Trinh is an internist in Chicago, IL. He received his medical degree from Northwestern University Feinberg School of Medicine and has been in practice 18 years. He specializes in hiv/aids medicine.
Education & Training
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1999 - 2002- Northwestern University The Feinberg School of MedicineClass of 1999
Certifications & Licensure
IL State Medical License 2002 - 2026- American Board of Internal Medicine Internal Medicine
Clinical Trials
- A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis Start of enrollment: 2014 Nov 24
- A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis Start of enrollment: 2014 Sep 01
Publications & Presentations
PubMed
- 16 citationsTURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on DarunavirDavid L. Wyles, Michael S. Saag, Rolando M Viani, Jacob Lalezari, Oluwatoyin Adeyemi
The Journal of Infectious Diseases. 2017-02-15 - 33 citationsPrevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 ProteaseThomas P. Young, Neil Parkin, Eric Stawiski, Tami Pilot-Matias, Roger Trinh
Antimicrobial Agents and Chemotherapy. 2010-11-01 - 292 citationsGlecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R. Foster, Stanley Wang, Armen Asatryan, Edward Gane
The New England Journal of Medicine. 2018-01-24
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
